Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147391 | 0.89 | CYP2D6 (0.42) | RETSLC6A4OPRM1CYP1A2CYP2C19 | |
| SCHEMBL20070181 | 0.83 | RET (0.41) | RETCYP1A2CYP2C19KMT2ALMNA | |
| SCHEMBL20147914 | 0.83 | CYP46A1 (0.48) | RETSLC6A4OPRM1LMNAGAA | |
| SCHEMBL13503756 | 0.76 | HSD11B1 (0.36) | RETOPRM1CYP1A2CYP2C19LMNA | |
| SCHEMBL20069006 | 0.75 | CYP2D6 (0.43) | SLC6A4OPRM1CYP1A2CYP2C19KMT2A | |
| SCHEMBL14028149 | 0.73 | ALDH1A1 (0.42) | OPRM1ALDH1A1HRH3 | |
| SCHEMBL22857003 | 0.72 | RET (0.49) | RETCYP1A2KMT2AALDH1A1CYP46A1 | |
| SCHEMBL20970566 | 0.71 | TP53 (0.52) | OPRM1CYP2C19LMNASIGMAR1HRH3 | |
| SCHEMBL20147400 | 0.71 | CYP46A1 (0.50) | RETSLC6A4OPRM1LMNAGAA | |
| SCHEMBL20137772 | 0.71 | GPR119 (0.49) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885SLC6A4 3586/4885OPRM1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.